Loading stock data…
XOMA Royalty Corporation (XOMA)
$40.17
Market Closed
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $310,000↓ | $1.43M↑ | $532,000↓ | $5.38M↑ | $4.32M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$480,000↓ | $2.18M↑ | -$1.33M↓ | $4.60M↓ | $5.93M |
| Net Income | $4.46M↓ | $6.10M↓ | $14.05M↑ | $9.19M↑ | $2.37M |
Peer Comparison
JNJUNHPFE
Fundamentals
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$522.96M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.56
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
29.95%
Volume
Today's trading volume
0
Recent News
Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings
Ligand Pharmaceuticals stock has delivered a very large 338.7% return over the past three years, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below that estimate while market multiples and a low overall value score point to a richer pricing. The 338.7% three year return puts a spotlight on whether the current price already embeds much of the good news in Ligand Pharmaceuticals. The completed US$739m...
XOMA Royalty (XOMA) Stock Fair Value Falls After Ligand Agrees Cash Acquisition
The fair value price target for XOMA Royalty has been reset from US$65.75 to US$39.00, now aligned with the agreed all cash acquisition price. Analysts are centering their narratives on this US$39 level as the key reference point for both valuation and deal related risk, which is shaping how they frame upside and downside from here. As you read on, you will see how this updated target fits into the evolving story around XOMA Royalty and what to watch as the transaction process moves...
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
Oncobiologics (OTLK) delivered earnings and revenue surprises of -33.33% and -97.09%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates
Kyntra Bio (KYNB) delivered earnings and revenue surprises of -11.48% and +140.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CG Oncology, Inc. (CGON) Reports Q1 Loss, Tops Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -23.33% and +80.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?